Barry Carter

Barry Carter

  • Patrick E. Keefe Professor in Pharmacy, Department of Pharmacy Practice and Science / Division of Health Services Research
  • Professor, Department of Family Medicine

Research Narrative

The long range goal of Dr. Carter’s research is to evaluate strategies to improve chronic disease control and minimize medication risk utilizing physician/pharmacist collaborative teams. Dr. Carter, an expert on hypertension, participated on writing panels for the JNC-5, 6 7 and 8 (2014) guidelines.

Dr. Carter has extensive experience conducting clinical trials including serving as principal investigator on six studies funded by the National Heart, Lung and Blood Institute within the National Institutes for Health. Two studies found that physician-pharmacist collaboration significantly improved blood pressure control in family medicine clinics in Iowa. Dr. Carter’s research team recently completed the Collaboration Among Pharmacists and physicians To Improve Outcomes Now (CAPTION) trial in 32 medical clinics across the United States. The CAPTION study evaluated the impact of physician-pharmacist collaboration on both hypertension and asthma and the extent to which the physician-pharmacist collaborative model is implemented in clinics that exhibit wide geographic, economic and racial diversity.

Dr. Carter is now the principal investigator for two studies that are evaluating a centralized cardiovascular risk service involving clinical pharmacists who are assisting primary care physicians with improving guideline adherence and patient medication adherence. The Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care (I-CARE) study is being conducted in 14 private medical offices throughout Iowa for patients at high risk for cardiovascular events such as heart attack and stroke. The MEDication Focused Outpatient Care for Underutilization of Secondary (MEDFOCUS) Prevention trial will be conducted in 20 primary care offices throughout the United States. MEDFOCUS will also recruit patients at high cardiovascular risk but this study will include many patients from racial and ethnic minority groups.